Pharmacokinetics of recombinant human interferon-α2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma

Anti-Cancer Drugs

Volumn 9, Issue 8, 1998, Pages 689-696

  Kim, Jeri ^a   Zhi, Jianguo ^b   Satoh, Hiroko ^b   Koss Twardy, Susan G ^b   Passe, Sharon M ^b   Patel, Indravadan H ^b   Pazdur, Richard ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

5 Fluorouracil; Colon carcinoma; Colorectal carcinoma; Interferon; Recombinant human interferon 2a

Indexed keywords

ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; PRIORITY JOURNAL; REMISSION; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0031788827     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199809000-00004     Document Type: Article

References (31)

1. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909-13.
2. Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15: 2910-9.
3. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-8.
4. Erlichman C, Fine S, Wong A, Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469-75.
5. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-17.
6. Pazdur R, Ajani JA, Patt YZ, et al. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 1990; 8: 2027-31.
7. Kemeny N, Younes A, Seiter K, et al. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Cancer 1990; 66: 2470-5.
8. Weh HJ, Platz D, Braumann D, et al. Phase II trial of 5-fluorouracil and recombinant interferon alfa-2b in metastatic colorectal carcinoma. Eur J Cancer 1992; 28A: 1820-3.
9. Diaz-Rubio E, Jimeno J, Camps C, et al. Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis. Cancer Invest 1992; 10: 259-64.
10. Wadler S, Schwartz EL, Goldman M, et al. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1769-75.
11. Wadler S, Lembersky B, Atkins M, Kirkwood J, Petrelli N. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1991; 9: 1806-10.
12. Lindley C, Bernard S, Gavigan M, Kaluzny B, Meadows L. Interferon-alpha increases 5-fluorouracil (5FU) plasma levels 64-fold within one hour: results of a phase I study. J Interferon Cytokine Res 1990; 10: (suppl 1): S132 (abstr II6-31).
13. Grem JL, McAtee N, Murphy RF, et al. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol 1991; 9: 1811-20.
14. Czejka MJ, Jager W, Schuller J, Fogl U, Schernthaner G. Pharmacokinetic aspects of the combination of interferon (α2b and folinic acid with fluorouracil. Arzneim-Forsch 1991; 41: 860-3.
15. Patel N, Joel SP, Seymour MT, Slevin ML, Wrigley PFM. Lack of pharmacokinetic interaction when interferon-α2a is added to a combination of 5-fluorouracil and folinic acid. BrJ Cancer 1992; 65 (suppl 16): 61 (abstr P124).
16. Sparano JA, Wadler S, Diasio RB, et al. Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. J Clin Oncol 1993; 11: 1609-17.
17. Danhauser LL, Freimann JH, Gilchrist TL, et al. Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol 1993; 11: 751-61.
18. Schuller J, Czejka M. Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid. Med Oncol 1995; 12: 47-53.
19. Staehelin T, Hobbs DS, Kung H-F, Pestka S. Purification of recombinant human leukocyte interferon (IFLrA) with monoclonal antibodies. Methods Enzymol 1981; 78: 505-12.
20. Bates CD, Watson DG, Willmott N, Logan H, Goldberg J. The analysis of 5-fluorouracil in human plasma by gas chromatography-negative ion chemical ionization mass spectrometry (GC-NICIMS) with stable isotope dilution. J Pharm Biomed Anal 1991; 9: 19-21.
21. Pazdur R, Bready B, Moore DF. Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinoma. Semin Oncol 1991; 18: 67-70.
22. Pazdur R, Ajani JA, Patt YZ, Gomez J, Bready B, Levin B. Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. Cancer 1993; 71: 1214-8.
23. Harris BE, Song R, Soong S-J, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197-201.
24. Hill M, Norman A, Cunningham D, et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 1995; 13: 2317-23.
25. Hill M, Norman A, Cunningham D, et al. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 1995; 13: 1297-302.
26. Greco FA, Figlin R, York M, et al. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 1996; 14: 2674-81.
27. Kosmidis PA, Tsavaris N, Skarlos D, et al. Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. J Clin Oncol 1996; 14: 2682-7.
28. The Corfu-A Study Group. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 1995; 13: 921-8.
29. Pazdur R, Ajani JA, Winn R, et al. A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma. Cancer 1992; 69: 878-82.
30. Pazdur R, Ajani JA, Abbruzzese JL, et al. Phase II evaluation of fluorouracil and recombinant α-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 1992; 70: 2073-6.
31. Wolmark N, Bryant J, Hyams DM, et al. The relative efficacy of 5-FU + leucovorin (FU-LV) and 5-FU-LV + interferon alfa-2a (IFN) in patients with Dukes' B and C carcinoma of the colon: first report of NSABP C-05. Proc Am Soc Clin Oncol 1998; 17: 255a (abstr 981).